Century Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
IPSC$1.81+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
| (a) | None. |
| (b) | The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted, amended, or terminated by our directors and officers during the three months ended December 31, 2025: |
| | | | | Trading Arrangement | | |
|---|---|---|---|---|---|---|
| Name · Title · Action · Effective Date · Rule 10b5-1 · Non-Rule 10b5-1 · Scheduled Expiration Date of Trading Plan (1) · Maximum Shares Subject to Trading Plan | ||||||
| Gregory Russotti | Chief Technology and Manufacturing Officer | Adoption | December 9, 2025 | X | December 31, 2026 | 160,000 |
(1)A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement, or as otherwise provided in the trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.